Patheon has signed an agreement to acquire a new active pharmaceutical ingredients (API) manufacturing facility in Florence, South Carolina, US, from Roche.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Under the agreement, the site will be purchased by Patheon for an immaterial sum, as well as the cost of associated inventory and spare parts.

Patheon has also signed a supply arrangement with Roche, which will help defray the costs associated with running the site for the next few years.

Patheon CEO James Mullen said: “As the only end-to-end provider of pharma development and manufacturing services, Patheon is uniquely positioned to integrate this new site into our global network and quickly leverage the capabilities with existing and new clients.

“The company will benefit from the additional North American API capacity and adds a state-of-the-art facility with approximately 200 scientific and manufacturing professionals.”

The Florence facility is expected have a similar financial profile to the company’s other sites in its drug substance segment.

"The company will benefit from the additional North American API capacity and adds a state-of-the-art facility with approximately 200 scientific and manufacturing professionals."

The 1,100 acre, 300,000ft² facility will have manufacturing capacity for API, ranging from development to manufacturing services.

With the addition of this site, Patheon will be able to expand its capacity for manufacturing highly potent compounds.

Furthermore, the acquisition will add capabilities to support solid-state chemistry, micronisation, and eventually, commercial spray drying.

The site features reactors ranging from 50l to 11,000l producing multiple products simultaneously, and will provide Patheon with a US API operation that can support products from clinical scale to commercial manufacturing.


Image: Florence, South Carolina, manufacturing site acquired by Patheon. Photo: courtesy of Business Wire.